Most common gene mutations by tissue type and histology

Tissue

Histology

Gene

 Mutation Found

 Quantity of Tests

Percent W/ Mutations

RSP

Adipocytes

Liposarcoma

TERT

54

169

32.0%

7.53E-06

PIK3CA

22

200

11.0%

1.20E-06

TP53

20

212

9.4%

4.93E-06

HRAS

4

101

4.0%

1.19E-05

FGFR3

1

28

3.6%

2.29E-06

CDKN2A

2

78

2.6%

9.40E-07

KRAS

2

91

2.2%

4.65E-07

CTNNB1

4

186

2.2%

5.25E-07

KIT

3

157

1.9%

2.31E-07

NF1

2

107

1.9%

6.61E-08

BRAF

1

54

1.9%

9.01E-08

Bone Marrow Cells

Chondroblastoma

H3F3B

74

87

85.1%

2.43E-04

H3F3A

5

86

5.8%

6.25E-06

Chondrosarcoma

IDH1

315

693

45.5%

2.40E-05

COL2A1

31

126

24.6%

7.40E-06

TP53

26

177

14.7%

7.67E-06

TTN

8

76

10.5%

3.74E-07

MUC16

6

76

7.9%

4.89E-07

MUC17

6

76

7.9%

2.04E-06

RYR2

6

76

7.9%

9.97E-08

IDH2

27

425

6.4%

3.42E-06

CDKN2A

14

278

5.0%

1.85E-06

PTCH1

5

116

4.3%

5.83E-07

Giant Cell Tumor

H3F3A

107

133

80.5%

8.65E-05

HRAS

1

2

50.0%

1.50E-04

BRAF

1

17

5.9%

2.86E-07

IDH1

1

60

1.7%

8.81E-07

IDH2

1

60

1.7%

8.97E-07

H3F3B

2

132

1.5%

4.33E-06

Osteosarcoma

TP53

75

291

25.8%

1.35E-05

MUC16

18

107

16.8%

1.04E-06

MUC4

12

107

11.2%

1.72E-06

ATRX

13

139

9.4%

3.32E-07

CDKN2A

28

365

7.7%

2.81E-06

RB1

16

210

7.6%

4.28E-07

APOB

8

107

7.5%

1.75E-06

TTN

8

107

7.5%

2.66E-07

Hepatocytes

Hepatocellular Carcinoma

TTN

305

1,021

29.9%

1.06E-06

TP53

1,234

4,236

29.1%

1.52E-05

TERT

593

2,265

26.2%

6.17E-06

CTNNB1

1,177

5,429

21.7%

5.29E-06

MUC16

201

984

20.4%

1.26E-06

OBSCN

130

982

13.2%

7.63E-07

AXIN1

200

1,628

12.3%

1.81E-06

ARID1A

142

1,183

12.0%

1.39E-06

PCLO

106

961

11.0%

2.69E-07

RYR2

104

962

10.8%

1.37E-07

CSMD1

97

957

10.1%

4.92E-08

SYNE1

83

963

8.6%

1.67E-07

Lymphocytes

Hodgkin's Lymphoma

SOCS1

11

24

45.8%

2.60E-04

TNFAIP3

24

74

32.4%

1.91E-05

NFKBIE

2

12

16.7%

2.19E-05

NRAS

6

40

15.0%

1.21E-05

TP53

3

26

11.5%

6.03E-06

MYC

26

56

46.4%

8.65E-05

ID3

17

53

32.1%

1.72E-04

TP53

70

338

20.7%

1.08E-05

FBXO11

8

53

15.1%

1.53E-06

GNA13

6

53

11.3%

2.38E-06

SMARCA4

6

53

11.3%

1.12E-06

ARID1A

8

82

9.8%

1.13E-06

DDX3X

5

53

9.4%

3.03E-06

PTEN

9

108

8.3%

7.68E-07

RHOA

10

131

7.6%

1.44E-06

Mature B-Cell Lymphoma

BCL2

89

286

31.1%

1.58E-06

KMT2D

103

335

30.7%

7.34E-06

TP53

180

866

20.8%

1.09E-05

CREBBP

83

436

19.0%

1.22E-06

PIM1

44

269

16.4%

3.10E-05

MYD88

262

1,712

15.3%

3.37E-05

SOCS1

55

371

14.8%

8.39E-05

B2M

40

283

14.1%

2.12E-05

EZH2

136

1,034

13.2%

1.70E-06

GNA13

34

268

12.7%

2.67E-06

SGK1

33

273

12.1%

8.12E-07

TNFAIP3

84

876

9.6%

5.64E-06

Precursor Cell Lymphoblastic Lymphoma

TET2

1

1

100.0%

7.47E-06

NOTCH1

111

193

57.5%

1.12E-05

NRAS

1

4

25.0%

2.01E-05

FBXW7

28

181

15.5%

7.20E-07

CTNNB1

1

9

11.1%

2.71E-06

WT1

1

14

7.1%

1.50E-06

T & NK-Cell Lymphoma

DDX3X

3

6

50.0%

1.60E-05

TP53

114

280

40.7%

2.13E-05

JAK3

25

71

35.2%

1.51E-05

BCOR

7

31

22.6%

1.79E-06

CTNNB1

35

155

22.6%

5.51E-06

KIT

29

158

18.4%

2.22E-06

KMT2C

5

31

16.1%

5.35E-07

AMER1

4

31

12.9%

6.26E-06

RHOA

3

26

11.5%

2.18E-06

STAT3

10

89

11.2%

1.49E-06

Neurons & Glia

Glioma

TP53

3,419

7,632

44.8%

2.34E-05

TERT

3,252

7,425

43.8%

1.03E-05

TTN

591

1,621

36.5%

1.30E-06

IDH1

6,930

19,128

36.2%

1.92E-05

ATRX

539

2,287

23.6%

8.38E-07

MUC16

246

1,349

18.2%

1.13E-06

H3F3A

532

3,146

16.9%

1.82E-05

CDKN2A

812

5,136

15.8%

5.79E-06

PTEN

783

5,022

15.6%

1.44E-06

CIC

247

2,034

12.1%

4.45E-06

EGFR

406

3,348

12.1%

6.44E-07

PIK3CA

316

2,961

10.7%

1.16E-06

Meningioma

NF2

508

1,518

33.5%

3.52E-06

TRAF7

107

378

28.3%

1.26E-05

KLF4

60

373

16.1%

3.30E-05

AKT1

111

1,429

7.8%

2.94E-06

TTN

5

65

7.7%

2.73E-07

CDKN2A

18

255

7.1%

2.59E-06

TERT

22

475

4.6%

1.09E-06

SMO

15

431

3.5%

1.41E-06

SMARCB1

7

279

2.5%

5.27E-07

TP53

5

226

2.2%

1.16E-06

Nerve Sheath Tumors

NF2

285

664

42.9%

4.52E-06

NF1

244

650

37.5%

1.33E-06

CDKN2A

27

201

13.4%

4.92E-06

TP53

33

316

10.4%

5.45E-06

TERT

5

108

4.6%

1.09E-06

SMARCB1

2

47

4.3%

8.94E-07

PDGFRA

2

99

2.0%

2.92E-07

BRAF

2

214

0.9%

4.55E-08

Neuroblastoma

ALK

364

4,473

8.1%

1.12E-07

MUC16

27

387

7.0%

4.32E-07

TTN

23

387

5.9%

2.11E-07

FLG

11

387

2.8%

1.23E-06

LRP1B

10

387

2.6%

1.36E-08

RYR1

10

387

2.6%

1.68E-07

AHNAK

9

387

2.3%

2.05E-07

AHNAK2

9

387

2.3%

5.66E-07

HMCN1

9

387

2.3%

5.10E-08

MUC17

9

387

2.3%

6.00E-07

MUC4

9

387

2.3%

3.57E-07

ARID1A

9

472

1.9%

2.22E-07

Vascular Endothelial Cells

Angiosarcoma

TP53

28

111

25.2%

1.32E-05

PTPRB

10

43

23.3%

1.93E-06

KRAS

27

118

22.9%

4.84E-06

CASP8

2

13

15.4%

2.83E-06

DNAH8

2

13

15.4%

4.88E-07

KDM6A

2

13

15.4%

6.43E-07

PCLO

2

13

15.4%

3.75E-07

TTN

2

13

15.4%

5.47E-07

PLCG1

7

48

14.6%

3.82E-06

KIAA0825

1

13

7.7%

1.64E-07

TMPRSS6

1

13

7.7%

1.74E-06

KDR

6

99

6.1%

1.28E-06